Melanotan II Research Profile (2026): The Non-Selective Melanocortin Analog

Melanotan II is the parent of a more famous descendant. Most readers encounter PT-141 first and only later learn that it was carved out of melanotan II — the original pigmentation-research peptide whose metabolite turned out to do something unexpected in the brain. But melanotan II is worth understanding on its own terms: it is a clean illustration of what non-selectivity means in melanocortin pharmacology, and an instructive case in how a research compound's status can diverge sharply from its popular reputation. This profile covers its discovery, structure, mechanism, and an honest read on where it stands — for laboratory research use only.

Framing up front: Melanotan II is not approved by the FDA or any major regulator for any human use, and it is not the same as its separately-approved metabolite. Everything below describes published research and mechanism, not guidance for human use. There are no cosmetic, tanning, or outcome claims here.

What melanotan II is

Melanotan II (commonly abbreviated MT-2) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous peptide that signals melanin production. Native α-MSH is a linear 13-residue peptide that is degraded quickly in the body. Melanotan II was engineered as a shorter, cyclic, far more stable and potent analog of that hormone.

Like its descendant PT-141, melanotan II is cyclic — the backbone is closed into a ring, a constraint that dramatically increases both potency and metabolic stability relative to native α-MSH. The functional contrast with PT-141 isn't in the ring; it's in the selectivity. Melanotan II is a broad, non-selective agonist across the melanocortin receptor family, whereas PT-141's profile shifted toward the central MC4R signaling.

Property	Value
Class	Cyclic non-selective melanocortin agonist (α-MSH analog)
Abbreviation	MT-2
Structure	Cyclic heptapeptide
Molecular formula	C₅₀H₆₉N₁₅O₉
Molecular weight	~1024 g/mol
Receptor targets	Non-selective: MC1R, MC3R, MC4R, MC5R
Regulatory status (US)	Research compound, not FDA-approved

Discovery: a more stable α-MSH

Melanotan II came out of research at the University of Arizona in the 1990s. The starting question was photoprotection: α-MSH stimulates melanin synthesis, and melanin is the body's own defense against UV damage, so a stable α-MSH analog was a rational tool for studying pigmentation and photoprotection. Native α-MSH was useless for sustained study because it degraded too fast, so the Arizona group designed cyclic, modified analogs that survived in the body and bound the melanocortin receptors more potently.

Melanotan II was one result. Its broad melanocortin activity made it a powerful research tool — but that same breadth is the root of both its scientific interest and its complications. The same program's observation that a melanotan-II metabolite produced central, arousal-related effects is what spun off the separate PT-141 program. In a real sense, melanotan II is the trunk from which two distinct research stories branched: pigmentation and central melanocortin signaling.

Mechanism: non-selective melanocortin agonism

The defining mechanistic fact about melanotan II is non-selectivity. The melanocortin receptor family has five members (MC1R through MC5R), each tied to different physiology, and melanotan II activates across the family rather than picking one.

• MC1R sits on melanocytes, the pigment-producing cells of the skin. Agonism here stimulates melanogenesis — the synthesis of melanin. This is the receptor activity melanotan II was designed to study.
• MC4R is expressed in the central nervous system and is involved in energy balance, appetite regulation, and — as the PT-141 story showed — sexual-arousal pathways. Melanotan II's MC4R activity is why it produces central effects beyond pigmentation.
• MC3R, MC5R add further physiological reach, contributing to the compound's broad activity profile.

That breadth is exactly what distinguishes melanotan II from a targeted analog. Where a selective compound engages one pathway, melanotan II pulls on several at once — which makes it a less clean research tool when isolating a single effect, and which underlies the broad and sometimes unpredictable activity reported in the literature. Our PT-141 profile covers how isolating MC4R signaling from this non-selective parent produced a more focused compound.

What the research has examined — and the honest caveats

The melanotan II literature centers on its pharmacology, but an honest profile has to be candid about the gap between research interest and validated safety.

• Melanogenesis and pigmentation. The core research line: how a stable α-MSH analog stimulates melanin synthesis via MC1R, and what that implies for photoprotection research.
• Appetite and energy-balance signaling. MC4R's central role in energy homeostasis made melanotan II a tool for studying appetite pathways in preclinical models.
• Central melanocortin effects. The arousal-related observations that motivated the PT-141 spin-off.

Here is the necessary, non-negotiable framing. Melanotan II has never completed the clinical development needed for approval, and it is not a validated or regulated product. Its non-selective activity is associated in the published and regulatory literature with a range of effects beyond pigmentation, and health authorities in multiple countries have issued warnings about unapproved melanotan products sold outside the research context. None of that is a basis for human use; it is the reason melanotan II remains, properly, a research compound only. We do not make cosmetic, tanning, or any outcome claims for it.

Melanotan II in the research-supplier market

In the research-compound market, melanotan II is widely available — it is one of the more commonly listed "other category" peptides. That ubiquity, combined with low per-vial cost, means the quality floor is wide and the low end is genuinely poor.

Two analytical points are specific to melanotan II. First, like PT-141 it is cyclic, so a real chromatogram and a correct mass (~1024 Da) confirm the cyclization actually worked. Second, melanotan II and PT-141 are structurally close cousins — similar mass, related sequence — which makes mass-spec identity confirmation more than a formality: it distinguishes the two and rules out mislabeled or substituted material. A supplier publishing only a bare purity figure, with no mass spec, has done less verification than the close structural relationship warrants.

For sourcing specifics, see our melanotan II where-to-buy guide and the where-to-buy index.

Quality markers for melanotan II

Marker	What to look for
HPLC purity	≥98% by reversed-phase HPLC, batch-specific
Mass spec	Observed mass ~1024 Da confirming the cyclic peptide (and distinguishing it from PT-141)
Third-party testing	Janoshik, MZ Biolabs, or equivalent independent lab
Lyophilization	Uniform white cake, no discoloration
Cold chain	Refrigerated transit
Documentation	Batch-specific COA tied to your lot

Our guide to reading a peptide COA explains how to separate a real certificate from a decorative one.

Storage and handling

Lyophilized melanotan II is stable refrigerated at 2-8°C, with long-term storage better at -20°C. Reconstituted in bacteriostatic water, solutions are typically handled within a few weeks under refrigeration, avoiding freeze-thaw cycling. These are general handling parameters consistent with published stability data, not protocol guidance.

Bottom line

Melanotan II is the non-selective trunk of the melanocortin research tree — a stable, cyclic α-MSH analog that activates broadly across the melanocortin receptors and, in doing so, both stimulated melanogenesis and revealed the central effects that became PT-141. Its breadth is its defining trait: a powerful, but blunt, research tool. And unlike its approved metabolite, melanotan II has never cleared the development needed for any human indication — a status worth stating plainly rather than papering over.

For laboratory sourcing, the cyclic structure and the close kinship with PT-141 make mass-spec identity confirmation, alongside batch-specific HPLC at ≥98%, the markers that matter most. Among US suppliers carrying melanotan II with that documentation, ROEHN Research is the one we point researchers toward.

For research use only. Not FDA-approved, not for human consumption; nothing here is a cosmetic or therapeutic claim.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity